通心络胶囊治疗冠心病的临床疗效及其安全性

Effect of Tongxinluo capsule on cardiovascular clinical events in patients with coronary heart disease

目的探讨通心络胶囊治疗冠心病的临床疗效及其安全性。方法选取北京市昌平区中医医院2019年3月—2020年3月收治的冠心病患者86例,按随机对照原则分为对照组和观察组,各43例。2组均经手术治疗,对照组术后给予常规治疗,观察组在对照组基础上给予通心络胶囊治疗。比较2组临床疗效、治疗前后血小板膜糖蛋白(GP)Ⅱb/Ⅲa受体复合物、血管内皮素1(ET-1)、一氧化氮(NO),并比较心血管临床事件发生率。结果观察组总有效率高于对照组(P<0.05)。治疗前2组GPⅡb/Ⅲa受体复合物、ET-1、NO比较,差异无统计学意义(P>0.05);治疗后观察组GPⅡb/Ⅲa受体复合物、ET-1低于对照组,NO高于对照组(P<0.05)。观察组心血管临床事件发生率低于对照组(P<0.05)。结论通心络胶囊治疗冠心病的临床疗效确切,可有效提高患者血管内皮功能,减少心血管临床事件发生。

Objective To investigate the clinical efficacy and safety of Tongxinluo capsule in the treatment of coronary heart disease.Methods A total of 86 cases of patients with coronary heart disease were selected from March 2019 to March 2020 in Beijing Changping District Hospital of Traditional Chinese Medicine,which were randomly divided into control group and observation group,43 cases in each group.The control group was given routine treatment after operation,and the observation group was given Tongxinluo capsule on the basis of the control group.The clinical efficacy,platelet membrane glycoprotein(GP) Ⅱ b/Ⅲ a a receptor complex,endothelin-1(ET-1)and nitric oxide(NO)were compared between the two groups before and after treatment,and the incidence of cardiovascular clinical events was compared.Results The total effective rate of the observation group was higher than that the control group(P<0.05).Before treatment,there was no significant difference in GP Ⅱ b/Ⅲ a a receptor complex,ET-1 and NO between the two groups(P>0.05);after treatment,GP Ⅱ b/Ⅲ a a receptor complex and ET-1 in the observation group were lower than those in the control group,and NO was higher than those in the control group(P<0.05).The incidence of cardiovascular clinical events in the observation group was lower than that in the control group(P<0.05).Conclusion Tongxinluo capsule has definite clinical effect in the treatment of coronary heart disease,which can effectively improve the vascular endothelial function of patients and reduce clinical cardiovascular events.